SN-38

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Retrieved on: 
Monday, April 8, 2024
Gene silencing, Irinotecan, Colorectal cancer, Immunotherapy, Triple-negative breast cancer, Mouse, Observation, Endocytosis, Cancer, Christian democracy, SN-38, Senior, Camptothecin, Conjugation, AACR, TSX, Treatment, Neoplasm, CRC, Poster, HT-29, TNBC, PDC, Vaccine

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.
  • The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads.
  • “In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform.
  • In the poster presented at AACR, the investigators noted that SORT1 gene silencing inhibits camptothecin-conjugate uptake in human HT-29 colorectal adenocarcinoma cells.

ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie

Retrieved on: 
Monday, March 25, 2024
Cloud, RB1, Hydrolysis, Irinotecan, Progression-free survival, Patient, SAN, Biomarker, Research, DNA, Cancer, Cmax, SN-38, Clinical trial, Curie Institute (Paris), Safety, Prodrug, Homologous recombination, ADC, TNBC, Teaching, PEG

Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).

Key Points: 
  • Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).
  • The TOPOLOGY trial is run by Institut Curie (Paris and Saint Cloud, France), with principal investigator Prof. Francois-Clement Bidard .
  • PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC.
  • Institut Curie has 3 sites (Paris, Saint-Cloud and Orsay) with over 3,700 health professionals working on treatment, research and teaching ([email protected]) Information on this clinical trial is available at clinicaltrials.gov, NCT06162351.

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Retrieved on: 
Monday, February 5, 2024
MYCN, Toxicity, SAN, Neoplasm, NCI, Glomus tumor, SN-38, DNA, Cmax, SLFN11, Clinical trial, Gene, Biomarker, Cell division, Patient, Safety, Irinotecan, Pros, Central nervous system, MYC, PEGylation, CNS, Phase, Medulloblastoma, TTY, Cancer, Bangladesh Technical Education Board, Ependymoma, Pharmaceutical industry

National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.

Key Points: 
  • National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
  • High levels of MYC drive oncogenesis in many cancers and induce DNA changes leading to the formation of “topoisome complexes”.
  • The NCI trial will assess whether PLX038 is safe and efficacious in primary CNS tumors driven by MYC or MYCN amplifications.
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].

ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors

Retrieved on: 
Wednesday, January 24, 2024
Patient, Progression-free survival, ADC, SAN, Half-life, SN-38, FDA, TNBC, BioDrugs, Pharmaceutical industry

In the article the authors inform: “Sacituzumab govitecan (Trodelvy®) is an antibody drug conjugate (ADC) of a humanized anti-TROP2 monoclonal antibody (mAb), linked to SN-38 — the active metabolite of the anti-cancer drug irinotecan and a potent inhibitor of topoisomerase 1.

Key Points: 
  • In the article the authors inform: “Sacituzumab govitecan (Trodelvy®) is an antibody drug conjugate (ADC) of a humanized anti-TROP2 monoclonal antibody (mAb), linked to SN-38 — the active metabolite of the anti-cancer drug irinotecan and a potent inhibitor of topoisomerase 1.
  • Sacituzumab govitecan has been remarkably effective in many clinical trials and is FDA-approved for patients with metastatic triple-negative breast cancer (TNBC) and pre-treated HR+/ HER2- metastatic breast cancer.
  • Hence, sacituzumab govitecan likely acts as a simple prodrug of systemic SN-38 as well as an ADC.
  • The authors posit that a long-acting SN-38, such as ProLynx PLX038, should be an efficacious and less toxic prodrug of systemic SN-38 than sacituzumab govitecan, and could serve as a therapy for certain forms of resistance mechanisms to sacituzumab govitecan.

ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic

Retrieved on: 
Friday, October 7, 2022
SAN, CA, ATM, PARP, Mayo Clinic, Clinical professor, Neoplasm, Woman, Mayo, Patient, Biotechnology, Carboplatin, RAD51, Hendrickson, DRS, Pharmacokinetics, PEG, Safety, Recurrence, Protein, GLOBE, Clinical trial, SLFN11, Death, Peptide, SN-38, Ovarian cancer, Biomarker, Pharmaceutical industry, Medical imaging, Irinotecan

SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic.

Key Points: 
  • SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic.
  • Carboplatin responses become shorter with each recurrence, and in platinum-resistant ovarian cancer the response rate to subsequent agents is only 15- to 20%.
  • Previous studies have shown that conventional inhibitors of the enzyme topoisomerase 1 have clinical activity in platinum-resistant ovarian cancer, and the Mayo trial seeks to improve this activity with the new PLX038.
  • Added ProLynx co-founder and President Daniel V. Santi Conventional short-acting topoisomerase 1 inhibitors have clinical activity in platinum-resistant ovarian cancer.

Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma

Retrieved on: 
Monday, October 12, 2020
Cancer treatments, Clinical medicine, Drugs, Antibody-drug conjugates, Immunomedics, Sacituzumab govitecan, Antibody-drug conjugate, TACSTD2, SN-38, Milatuzumab

This orphan drug designation is an important milestone for Immunomedics as we strive to broaden the clinical utility of Trodelvy, said Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics.

Key Points: 
  • This orphan drug designation is an important milestone for Immunomedics as we strive to broaden the clinical utility of Trodelvy, said Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics.
  • Trodelvy (sacituzumab govitecan-hziy) is the lead product and the most advanced program in Immunomedics unique antibody-drug conjugate (ADC) platform.
  • Trodelvy is an ADC that is directed against Trop-2, a cell-surface protein expressed in many solid cancers.
  • Trodelvy binds to Trop-2 and delivers the anti-cancer drug, SN-38, to kill cancer cells.

PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUG

Retrieved on: 
Monday, June 1, 2020
Drugs, Health, Organic compounds, SN-38, Irinotecan, Food and Drug Administration, Sacituzumab govitecan

ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan.

Key Points: 
  • ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan.
  • This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan.
  • The wider therapeutic window will likely lead to more patients responding with less side effects when on ATT-11T compared to irinotecan.
  • The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings.

Tarveda Therapeutics Presents Pharmacokinetic and Tumor Biopsy Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting

Retrieved on: 
Monday, April 27, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, RTT, Organic compounds, Chemical compounds, Heterocyclic compounds, Irinotecan, Cancer, SN-38

Unconjugated SN-38 remained very low at approximately 2% of the PEN-866 exposure in circulation, said Mark Bilodeau, Ph.D., Chief Scientific Officer of Tarveda.

Key Points: 
  • Unconjugated SN-38 remained very low at approximately 2% of the PEN-866 exposure in circulation, said Mark Bilodeau, Ph.D., Chief Scientific Officer of Tarveda.
  • These data are consistent with PEN-866 preclinical data showing materially increased uptake and retention of PEN-866 in the tumor versus untargeted forms of SN-38, such as irinotecan.
  • These biopsy results support previous preclinical data showing that PEN-866 slowly releases its SN-38 payload in the tumor over multiple days.
  • The anti-cancer payload is retained in tumor and then released over time causing the anti-cancer payload to become active in the tumor.